JP2009528293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009528293A5 JP2009528293A5 JP2008556560A JP2008556560A JP2009528293A5 JP 2009528293 A5 JP2009528293 A5 JP 2009528293A5 JP 2008556560 A JP2008556560 A JP 2008556560A JP 2008556560 A JP2008556560 A JP 2008556560A JP 2009528293 A5 JP2009528293 A5 JP 2009528293A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acids
- factor
- nucleic acid
- active form
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 108010014172 Factor V Proteins 0.000 claims 7
- 230000002950 deficient Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108010054218 Factor VIII Proteins 0.000 claims 3
- 102000001690 Factor VIII Human genes 0.000 claims 3
- 208000009292 Hemophilia A Diseases 0.000 claims 3
- 229960000301 factor viii Drugs 0.000 claims 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 208000009429 hemophilia B Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 208000001593 Bernard-Soulier syndrome Diseases 0.000 claims 1
- 206010067787 Coagulation factor deficiency Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000028702 Congenital thrombocyte disease Diseases 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102000004210 Vitamin K Epoxide Reductases Human genes 0.000 claims 1
- 108090000779 Vitamin K Epoxide Reductases Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 230000010100 anticoagulation Effects 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 208000014763 coagulation protein disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000004521 platelet storage pool deficiency Diseases 0.000 claims 1
- 230000008742 procoagulation Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77612406P | 2006-02-23 | 2006-02-23 | |
| PCT/US2007/062720 WO2007101106A2 (en) | 2006-02-23 | 2007-02-23 | Compositions and methods for modulating hemostasis using variant forms of activated factor v |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009528293A JP2009528293A (ja) | 2009-08-06 |
| JP2009528293A5 true JP2009528293A5 (cg-RX-API-DMAC7.html) | 2010-04-15 |
Family
ID=38459752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008556560A Pending JP2009528293A (ja) | 2006-02-23 | 2007-02-23 | 様々な形態の活性型第ｖ因子を用いた止血を調節する組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8236764B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1986681A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009528293A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007220825B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2641519A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL193306A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007101106A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010060035A1 (en) * | 2008-11-21 | 2010-05-27 | The Children's Hospital Of Philadelphia | Snake factor v and methods of use as a procoagulant |
| US20120065137A1 (en) * | 2010-09-03 | 2012-03-15 | Richard Jenny | Therapeutics for trauma induced factor v consumptive coagulopathy |
| US8637448B2 (en) * | 2010-09-14 | 2014-01-28 | University Of Rochester | Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface |
| CA2851844A1 (en) | 2011-10-13 | 2013-04-18 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating thrombin generation |
| WO2016005564A2 (en) * | 2014-07-11 | 2016-01-14 | Novo Nordisk A/S | Antibodies against activated factor v |
| CA3077084A1 (en) | 2017-10-05 | 2019-04-11 | Epivax, Inc. | Regulatory t cell epitopes |
| WO2019210187A1 (en) * | 2018-04-26 | 2019-10-31 | The University Of North Carolina At Chapel Hill | Methods and compositions for treatment of hemophilia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093699A (en) | 1987-07-09 | 2000-07-25 | The University Of Manitoba | Method for gene therapy involving suppression of an immune response |
| WO1994017810A1 (en) | 1993-02-12 | 1994-08-18 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| CA2160583A1 (en) | 1993-04-16 | 1994-10-27 | Stanley A. Plotkin | Recombinant cytomegalovirus vaccine |
| AU7676894A (en) | 1993-08-27 | 1995-03-21 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Convection-enhanced drug delivery |
| AT401270B (de) | 1994-09-26 | 1996-07-25 | Immuno Ag | Verfahren zur quantifizierung von genomischer dna |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| CA2188575A1 (en) | 1995-02-28 | 1996-09-06 | H. Kirk Hammond | Gene transfer-mediated angiogenesis therapy |
| WO1997032481A1 (en) | 1996-03-07 | 1997-09-12 | The Regents Of The University Of California | Helper-free, totally defective adenovirus for gene therapy |
| WO2003100053A1 (en) | 2002-05-22 | 2003-12-04 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hemophilia a |
-
2007
- 2007-02-23 WO PCT/US2007/062720 patent/WO2007101106A2/en not_active Ceased
- 2007-02-23 CA CA002641519A patent/CA2641519A1/en not_active Abandoned
- 2007-02-23 AU AU2007220825A patent/AU2007220825B2/en not_active Ceased
- 2007-02-23 EP EP07757412A patent/EP1986681A4/en not_active Withdrawn
- 2007-02-23 EP EP11176416A patent/EP2384764A3/en not_active Withdrawn
- 2007-02-23 US US12/162,935 patent/US8236764B2/en active Active
- 2007-02-23 JP JP2008556560A patent/JP2009528293A/ja active Pending
-
2008
- 2008-08-07 IL IL193306A patent/IL193306A/en active IP Right Grant
-
2012
- 2012-07-25 US US13/557,882 patent/US8470557B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009528293A5 (cg-RX-API-DMAC7.html) | ||
| Broze Jr | Tissue factor pathway inhibitor | |
| Vine | Recent advances in haemostasis and thrombosis | |
| Martinez et al. | The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation | |
| Kenne et al. | Factor XII: a drug target for safe interference with thrombosis and inflammation | |
| JP2008539775A5 (cg-RX-API-DMAC7.html) | ||
| Krupiczojc et al. | Coagulation signalling following tissue injury: focus on the role of factor Xa | |
| AU2014301041B2 (en) | Combination therapy using a Factor XII inhibitor and a C1-Inhibitor | |
| Noble et al. | Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease | |
| JP7072577B2 (ja) | ＦＸＩａ抗体のための新規で安定な製剤 | |
| JP2005538046A5 (cg-RX-API-DMAC7.html) | ||
| JP2013519697A5 (cg-RX-API-DMAC7.html) | ||
| JP2013505286A5 (cg-RX-API-DMAC7.html) | ||
| JP2010526103A5 (cg-RX-API-DMAC7.html) | ||
| Zhu et al. | High mobility group box 1 protein as a potential drug target for infection-and injury-elicited inflammation | |
| JP2021503891A5 (cg-RX-API-DMAC7.html) | ||
| Toltl et al. | Protective effects of activated protein C in sepsis | |
| Rengasamy et al. | Bioactive peptides and proteins as alternative antiplatelet drugs | |
| US20240124534A1 (en) | Anticoagulant fusion proteins and uses thereof | |
| EP1332159A1 (en) | Process for the preparation of latent antithrombin iii | |
| Shu et al. | Antimicrobial peptide cathelicidin-BF inhibits platelet aggregation by blocking protease-activated receptor 4 | |
| Abo-Salem et al. | Reversal of novel oral anticoagulants | |
| CN102391360A (zh) | 一种抗血栓和血小板聚集的小肽 | |
| EP3247332A1 (en) | Unit aerosol doses for anticoagulation | |
| JP2014507147A5 (cg-RX-API-DMAC7.html) |